Bionano Genomics, Inc. (BNGO)
- Previous Close
0.7606 - Open
0.7700 - Bid 0.7910 x 400
- Ask 0.8300 x 800
- Day's Range
0.7700 - 0.8100 - 52 Week Range
0.7100 - 8.2000 - Volume
820,875 - Avg. Volume
1,555,437 - Market Cap (intraday)
48.642M - Beta (5Y Monthly) 2.37
- PE Ratio (TTM)
-- - EPS (TTM)
-6.8100 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.67
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
www.bionano.comRecent News: BNGO
Performance Overview: BNGO
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNGO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNGO
Valuation Measures
Market Cap
48.64M
Enterprise Value
26.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.75
Price/Book (mrq)
0.51
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
-0.12
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.39%
Return on Equity (ttm)
-134.56%
Revenue (ttm)
36.12M
Net Income Avi to Common (ttm)
-232.49M
Diluted EPS (ttm)
-6.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
66.77M
Total Debt/Equity (mrq)
82.59%
Levered Free Cash Flow (ttm)
-97.73M